Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.34 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21385642 | 0.84 | GBA1 (0.42) | GBA1MAN1B1 | |
| SCHEMBL18663784 | 0.84 | GBA1 (0.42) | GBA1MAN1B1 | |
| SCHEMBL21385649 | 0.82 | GBA1 (0.32) | GBA1MAN1B1 | |
| SCHEMBL18663789 | 0.82 | GBA1 (0.32) | GBA1MAN1B1 | |
| SCHEMBL20427576 | 0.82 | GBA1 (0.32) | GBA1MAN1B1 | |
| SCHEMBL12044972 | 0.82 | CCR5 (0.32) | GBA1 | |
| SCHEMBL6522910 | 0.76 | MAN1B1 (0.33) | GBA1MAN1B1FUCA1GLAGAA | |
| SCHEMBL20427569 | 0.76 | MAN1B1 (0.33) | GBA1MAN1B1FUCA1GLAGAA | |
| SCHEMBL18663771 | 0.76 | MAN1B1 (0.33) | GBA1MAN1B1FUCA1GLAGAA | |
| SCHEMBL6522918 | 0.76 | MAN1B1 (0.33) | GBA1MAN1B1FUCA1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | 2022-05-12 | — | — | US | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | AMGEN INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3297989-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2016191312-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AP3M1, GPBAR1 | GBA1 4717/4885MAN1B1 3355/4885FUCA1 4738/4885 |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | GBA1 4427/4885MAN1B1 2664/4885FUCA1 4591/4885 |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | GBA1 4587/4885MAN1B1 2438/4885FUCA1 4704/4885 |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | GBA1 4283/4885MAN1B1 2071/4885FUCA1 4471/4885 |
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | CDK7, CDK8, CDK3 | GBA1 3083/4885MAN1B1 4746/4885FUCA1 4499/4885 |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, APLNR | GBA1 4855/4885MAN1B1 1926/4885FUCA1 4391/4885 |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | GBA1 4819/4885MAN1B1 3222/4885FUCA1 4810/4885 |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, APLNR | GBA1 4587/4885MAN1B1 2438/4885FUCA1 4704/4885 |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | TBXA2R, AP3M1, GPBAR1 | GBA1 4717/4885MAN1B1 3355/4885FUCA1 4738/4885 |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | TBXA2R, AGTR1, APLNR | GBA1 4855/4885MAN1B1 1926/4885FUCA1 4391/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | GBA1 4825/4885MAN1B1 3158/4885FUCA1 4838/4885 |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | GBA1 4283/4885MAN1B1 2071/4885FUCA1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.